Abstract:Editor-in-Chief, reviews two of the most remarkable papers published in The Chinese Journal of Cardiology (CJC). Transcatheter aortic valve replacement (TAVR) has become an established and increasingly used approach for the management of severe symptomatic aortic stenosis (AS) or regurgitation throughout the surgical risk spectrum, showing similar, or even superior outcomes compared with standard surgical aortic valve replacement. Despite an iteration in TAVR device technologies and improved patient selection and management through the multidisciplinary heart teams, challenges, and controversies exist regarding the balancing of ischaemic and bleeding risks in these patients and the optimal antithrombotic regimens to adopt after TAVR are still unclear. This was recently reported in the CJC with a contribution entitled ‘One-year follow-up results of atrial fibrillation (AF) patients who undergoing transcatheter aortic valve implantation’ by Prof. Yaling Han and colleagues from General Hospital of Northern Theater Command. This is a single-centre retrospective study. A total of 115 patients with severe AS who were admitted to the hospital from May 2016 to November 2020 and successfully received TAVR were included. According to the absence or presence of AF pre-TAVR, they were divided into the AF group (n= 21) and the non-AF group (n= 94). The patients were followed up for postoperative antithrombotic treatment and the occurrence of the net adverse clinical and cerebrovascular events (NACCEs) at 12 months post-TAVR, including cardiac death, readmission to hospital for heart failure, non-fatal myocardial infarction, ischaemic stroke, and major bleeding [Bleeding Academic Research Consortium (BARC) levels 3–5]. Among the 115 selected patients, age was (73.8+ 6.9) years, there were 63 males. In terms of postoperative antithrombotic therapy, 48.9% (46/94) of the patients in the non-AF group received monotherapy and 47.9% (45/94) received dual antiplatelet therapy (DAPT). In the AF group, 47.6% (10/21) received anticoagulants and 33.3% (7/21) received DAPT. The proportion of patients in the AF group taking non-vitamin K antagonist oral anticoagulants (NOACs) was higher than that in the non-AF group [38.1% (8/21) vs. 2.1% (2/94), P, 0.001]. During the 12 months follow-up, the incidence of NACCE after TAVR was 14.3% (3/21) in the AF group, which was numerically higher than that in the non-AF group [6.4% (6/94)], while the difference was not statistically significant (P= 0.441, Table 1). The incidence of major bleeding was significantly higher in the AF group than in the non-AF group [9.5% (2/21) vs. 0.0%, P= 0.032, Table 1]. Univariate logistic regression analysis showed that hypertension was associated with the risk of NACCE (OR= 8.308, P= 0.050), while AF was not associated with the risk of NACCE (P= 0.235). Therefore, the incidence of severe bleeding after TAVR is higher in

Academic Research Consortium High Bleeding Risk Criteria associated with 2-year bleeding events and mortality after transcatheter aortic valve replacement discharge: a Japanese Multicentre Prospective OCEAN-TAVI Registry Study

Clinical impact of Academic Research Consortium for High Bleeding-Risk scores on clinical outcomes in patients with stable coronary artery disease undergoing percutaneous coronary intervention

Validation of the Valve Academic Research Consortium High Bleeding Risk Definition in Patients Undergoing TAVR

Defining high bleeding risk in patients undergoing transcatheter aortic valve implantation: a VARC-HBR consensus document

Development and Validation of a Practical Model to Identify Patients at Risk of Bleeding after TAVR

Japanese high bleeding risk criteria status predicts low thrombogenicity and bleeding events in patients undergoing percutaneous coronary intervention

Ankle–brachial pressure index as a predictor of the 2-year outcome after transcatheter aortic valve replacement: data from the Japanese OCEAN-TAVI Registry

Meta-analysis of Predictors of Early Severe Bleeding in Patients Who Underwent Transcatheter Aortic Valve Implantation.

Transcatheter Aortic Valve Replacement for Bicuspid Vs. Tricuspid Aortic Stenosis among Patients at Low Surgical Risk in China: from the Multicenter National NTCVR Database

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement

PERCUTANEOUS CORONARY INTERVENTION FOR LEFT MAIN DISEASE IN HIGH BLEEDING RISK: OUTCOMES FROM A SUBANALYSIS OF THE DELTA 2 REGISTRY

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk

Effect of the urgency and landing zone on rates of in-hospital death, stroke, and paraplegia after thoracic endovascular aortic repair in Japan

Impact of the Hospital Frailty Risk Score on Outcomes After Transcatheter Aortic Valve Replacement in Late Elderly Patients

Development and assessment of total thrombus-formation analysis system-based bleeding risk model in patients undergoing percutaneous coronary intervention

Determining risk factors for vascular and bleeding complications after TAVR using CT angiography

Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial

Risk of mortality following transcatheter aortic valve replacement for low-flow low-gradient aortic stenosis

Impact of the completeness of revascularization and high bleeding risk status in acute coronary syndrome patients with multi-vessel disease: A retrospective analysis

Correlations Between Plasma BNP Level and Risk of Thrombotic-Hemorrhagic Events After Left Atrial Appendage Closure

Midterm Outcome of Transcatheter Versus Surgical Aortic Valve Replacement in Low to Intermediate Risk Patients: A Meta-Analysis of Randomized Controlled Trials.